建立转化暴露-包围方法以简化激素避孕药产品开发
全球922百万育龄妇女使用避孕措施,口服复方激素避孕药(CHC)含孕激素和雌激素,主要经CYP3A4代谢,存在代谢性药物相互作用(DDI)风险。美国FDA发布指南建议避免CYP3A4诱导相互作用。本研究采用基于生理的药代动力学模型、比较CYP3A诱导剂和抑制剂对屈螺酮(DRSP)与左炔诺孕酮(LNG)的影响及真实世界数据,探讨不同孕激素的DDI风险差异。
要点
- 口服CHC的代谢性DDI主要涉及CYP3A4,FDA指南建议避免CYP3A4诱导相互作用。
- 不同孕激素的CYP3A4代谢分数(fmCYP3A4)不同,LNG最低而DRSP最高。
- 研究采用PBPK模型、DDI比较和真实世界数据多管齐下评估DDI风险差异。
核心结论
- 不同孕激素对CYP3A4介导的代谢性DDI风险可能存在差异,LNG和DRSP分别处于利福平诱导效应的边缘。
研究设计与样本
- 研究采用多管齐下策略:开发基于生理的药代动力学模型;比较CYP3A诱导剂和抑制剂对DRSP与LNG的影响;基于真实世界数据提供临床实践背景。
主要发现
- LNG和DRSP是常用孕激素,在体内利福平诱导效应中处于边缘,因其在常用CHC配方中fmCYP3A4分别相对最低和最高。
关键数值与推荐
- 美国FDA发布指南,针对CHC领域的代谢性DDI,建立基于类别的总体推荐,避免CYP3A4诱导相互作用。
临床怎么用
- 临床应关注CHC与CYP3A4诱导剂或抑制剂的相互作用,不同孕激素的DDI风险可能不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Worldwide, 922 million women of reproductive age (or their partners) use some sort of contraception to prevent pregnancy. Oral combined hormonal contraceptives (CHCs) typically utilize a combination of a progestin and an estrogen. CHCs are potentially at risk to metabolic drug-drug interaction (DDI) via CYP3A4, the main enzyme involved in the oxidative metabolism of ethinyl estradiol and most progestins (e.g., levonorgestrel (LNG) and drospirenone (DRSP)). Recently, the US Food and Drug Administration (FDA) issued a guidance addressing metabolic DDIs in the realm of CHC, establishing an overall class-based recommendation with respect to avoidance of CYP3A4 induction interactions. Given that different progestins have varying magnitudes of fraction metabolized by CYP3A4 (fmCYP3A4 ), it would be of clinical benefit to determine if all progestins are at the same risk to CYP3A4-mediated metabolic DDIs. LNG and DRSP are commonly used progestins that are at the margins of the rifampicin induction effect observed in vivo because they have the relatively lowest and highest fmCYP3A4 among commonly used CHC formulations containing norgestimate, desogestrel, norgestrel, and norethindrone. Therefore, we applied a multi-pronged strategy (i.e., (i) development of the physiologically-based pharmacokinetic models; (ii) comparison of the effect of CYP3A inducers and inhibitors on DRSP vs. LNG; and (iii) providing the clinical-practice context based on real-world data, to explore the difference in DDI risk for oral CHCs.
引用
- Cicali B, Da Silva L, Sarayani A, et al. Development of a Translational Exposure-Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products. Clin Pharmacol Ther. 2022. PMID: 35723889. doi:10.1002/cpt.2690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。